171 related articles for article (PubMed ID: 18553237)
21. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
22. Cytokines in combination with chemotherapy for advanced renal carcinoma--the importance of patient selection.
Joffe JK; Patel PM; Banks RE; Selby PJ
Cancer Biother Radiopharm; 1996 Oct; 11(5):309-13. PubMed ID: 10851510
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
25. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Negrier S; Perol D; Ravaud A; Chevreau C; Bay JO; Delva R; Sevin E; Caty A; Escudier B;
Cancer; 2007 Dec; 110(11):2468-77. PubMed ID: 17932908
[TBL] [Abstract][Full Text] [Related]
26. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract][Full Text] [Related]
28. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Huland E; Heinzer H; Huland H
J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
[TBL] [Abstract][Full Text] [Related]
29. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
[TBL] [Abstract][Full Text] [Related]
30. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
31. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
Donskov F; von der Maase H; Henriksson R; Stiemer U; Wersäll P; Nellemann H; Hellstrand K; Engman K; Naredi P
Ann Oncol; 2002 Mar; 13(3):441-9. PubMed ID: 11996477
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
Koulova L; Novik Y; Caliendo G; Wiernik P; Dutcher J
J Immunother; 2005; 28(6):576-81. PubMed ID: 16224275
[TBL] [Abstract][Full Text] [Related]
35. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.
Joffe JK; Banks RE; Forbes MA; Hallam S; Jenkins A; Patel PM; Hall GD; Velikova G; Adams J; Crossley A; Johnson PW; Whicher JT; Selby PJ
Br J Urol; 1996 May; 77(5):638-49. PubMed ID: 8689103
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma.
Witte RS; Leong T; Ernstoff MS; Krigel RL; Oken MM; Harris J; Tormey DC; Trump DL
Invest New Drugs; 1995; 13(3):241-7. PubMed ID: 8729953
[TBL] [Abstract][Full Text] [Related]
38. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
40. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
